You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

四環醫藥(00460.HK)附屬注射液產品臨床申請獲受理

阿思達克 06-13 12:02
四環醫藥(00460.HK)公布，非全資附屬惠升生物製藥研發的司美格魯(月太)注射液，用於治療2型糖尿病的臨床試驗申請，近日已獲得中國國家藥監局受理，為該公司提交臨床實驗申請的首個胰高血糖素樣(月太)-1(GLP-1)類似物。
四環醫藥(00460.HK)
20240617四環醫藥00460
Relevant Stocks
四環醫藥(00460.HK)
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.